Perrigo CoPRGO +3.38%44 EPS without NRI is $2.54 as of Mar. 2026. GuruFocus rates PRGO with a GF Score™ of 44/100 and a GF Value™ of $24.98 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 784 Drug Manufacturers companies, Perrigo Co ranks better than 50.51% on this metric.
Perrigo Co's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.40.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $2.54.
During the past 12 months, Perrigo Co's average earnings per share (NRI) Growth Rate was -11.50% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 9.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -2.90% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was -5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Perrigo Co's EPS without NRI or its related term are showing as below:
PRGO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.2 Med: 7.7 Max: 140.1
Current: 9.9
During the past 13 years, Perrigo Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 140.10% per year. The lowest was -58.20% per year. And the median was 7.70% per year.
PRGO's 3-Year EPS without NRI Growth Rate is ranked better than 50.51% of 784
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs PRGO: 9.90
Perrigo Co's EPS (Diluted) for the
three
months ended in Mar. 2026 was $-2.87.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.10.
Perrigo Co's EPS (Basic) for the
three
months ended in Mar. 2026 was $-2.87.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.10.
Perrigo Co (NYSE:PRGO) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Perrigo Co EPS without NRI Related Terms
Perrigo Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for Perrigo Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRGO vs XERS, PAHC, ALVO: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Perrigo Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (PRGO) has a EPS without NRI of $2.54 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Perrigo Co and its competitors. According to the industry distribution chart, Perrigo Co ranks #388 out of 784 companies in the Drug Manufacturers industry, placing it in the top 49.5%.
Is Perrigo Co's EPS without NRI too high?
Perrigo Co's current EPS without NRI is $2.54. The Drug Manufacturers industry median EPS without NRI is 9.70. Perrigo Co's value of $2.54 is 73.8% below this industry median. Based on the distribution chart, Perrigo Co ranks #388 out of 784 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Perrigo Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's EPS without NRI compare to XERS and PAHC?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #388 out of 784 companies for EPS without NRI. This puts Perrigo Co in the upper half of its industry. The industry median EPS without NRI is 9.70. Perrigo Co's value of $2.54 is 73.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current EPS without NRI of $2.54 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current EPS without NRI is $2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $24.98, compared to a current price of $10.39 — trading 58.4% below its estimated fair value. The current EPS without NRI is $2.54 and 73.8% below the Drug Manufacturers industry median of 9.70. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Perrigo Co (PRGO), the current EPS without NRI is $2.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $10.39 is trading 58.4% below its estimated GF Value™ of $24.98.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
EPS without NRI: $2.54
GF Value™: $24.98 vs. price of $10.39 (58.4% below fair value)
Industry Position: 73.8% below the Drug Manufacturers median (#388 of 784)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for PRGO
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
